ReviewBritish journal of pharmacology2009
Protective mechanisms of activated protein C in severe inflammatory disorders.
Review in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.Critical care (London, England) · 2010Trial
- Fulminant Thromboinflammatory Syndrome Following an Influenza-like Illness in an Adolescent: Clinical Insights from a Case Report.International journal of molecular sciences · 2026Article
- Arterial Thrombosis in Acute Respiratory Infections: An Underestimated but Clinically Relevant Problem.Journal of clinical medicine · 2024Review
- Article
- Unraveling the Molecular Mechanisms of Activated Protein C (APC) in Mitigating Reperfusion Injury and Cardiac Ischemia: a Promising Avenue for Novel Therapeutic Interventions.Journal of cardiovascular translational research · 2024Review
- Proteomics data in vitiligo: a scoping review.Frontiers in immunology · 2024Article
- Multi-Omic Admission-Based Prognostic Biomarkers Identified by Machine Learning Algorithms Predict Patient Recovery and 30-Day Survival in Trauma Patients.Metabolites · 2022Article
- Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology.Journal of clinical medicine · 2022Review
- The extract from Agkistrodon halys venom protects against lipopolysaccharide (LPS)-induced myocardial injury.BMC complementary and alternative medicine · 2019Article
- Review
- Article
- Bilateral iliac and popliteal arterial thrombosis in a child with focal segmental glomerulosclerosis.Korean journal of pediatrics · 2016Article
- Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis.Experimental and therapeutic medicine · 2015Article
- Observational
- Biased signaling of protease-activated receptors.Frontiers in endocrinology · 2014Review
- Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view.Mediators of inflammation · 2013Review
- Article
- Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice.American journal of respiratory cell and molecular biology · 2011Article
- Simvastatin is protective during Staphylococcus aureus pneumonia.Current pharmaceutical biotechnology · 2011Article
- A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis.EMBO molecular medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The protein C system is an important natural anticoagulant mechanism mediated by activated protein C (APC) that regulates the activity of factors VIIIa and Va. Besides well-defined anticoagulant properties, APC also demonstrates anti-inflammatory, anti-apoptotic and endothelial barrier-stabilizing effects that are collectively referred to as the cytoprotective effects of APC. Many of these beneficial effects are mediated through its co-receptor endothelial protein C receptor, and the protease-activated receptor 1, although exact mechanisms remain unclear and are likely pleiotropic in nature. Increased insight into the structure-function relationships of APC facilitated design of APC variants that conserve cytoprotective effects and reduce anticoagulant features, thereby attenuating the risk of severe bleeding with APC therapy. Impairment of the protein C system plays an important role in acute lung injury/acute respiratory distress syndrome and severe sepsis. The pathophysiology of both diseases states involves uncontrolled inflammation, enhanced coagulation and compromised fibrinolysis. This leads to microvascular thrombosis and organ injury. Administration of recombinant human APC to correct the dysregulated protein C system reduced mortality in severe sepsis patients (PROWESS trial), which stimulated further research into its mechanisms of action. Several other clinical trials evaluating recombinant human APC have been completed, including studies in children and less severely ill adults with sepsis as well as a study in acute lung injury. On the whole, these studies have not supported the use of APC in these populations and challenge the field of APC research to search for additional answers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.